Evaluation of the Potential Protective Effects of Strains Against Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial

Overview

Journal Can J Infect Dis Med Microbiol

Publisher Wiley

Date 2022 Oct 4

PMID 36193094

Authors

Shumin Wang

Meiyi Zhang

Leilei Yu

Fengwei Tian

Wenwei Lu

Gang Wang

Wei Chen

Jialin Wang

Qixiao Zhai

Affiliations

Soon will be listed here.

Abstract

Background: The beneficial effects of probiotic supplementation standard antibiotic therapies for infection have been verified, but the ability of probiotic monotherapy to eradicate remains unclear.

Aim: To evaluate the accuracy and efficacy of specific strains against infection.

Methods: Seventy-eight patients with infection were treated with strain G14-5M ( CCFM1118) or M2-09-R02-S146 ( CCFM1121) or CCFM8610 at a dose of 2 g twice daily for one month. C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the strains in eradicating infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial.

Results: The C-urea breath test value of the three treatment groups had decreased significantly, and the eradication rate of had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, =0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate infection. The ingestion of strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of -infected patients appeared to modulate the gut microbiota of patients. However, none of the strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor concentrations, or serum pepsinogen concentrations in the patients.

Conclusion: Three strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of -infected patients. The activity of probiotics in eradicating infection may be species/strain specific.

Citing Articles

Targeting Through the "Muco-Microbiotic Layer" Lens: The Challenge of Probiotics and Microbiota Nanovesicles.

Manna O, Caruso Bavisotto C, Gratie M, Damiani P, Bonaventura G, Cappello F Nutrients. 2025; 17(3).

PMID: 39940427 PMC: 11819664. DOI: 10.3390/nu17030569.

Effects of Lactobacillus spp. on Helicobacter pylori: A Promising Frontier in the Era of Antibiotic Resistance.

Dash D, Mishra V, Panda M, Pathak S Probiotics Antimicrob Proteins. 2024; .

PMID: 39499454 DOI: 10.1007/s12602-024-10396-z.

Therapeutic Approach Targeting Gut Microbiome in Gastrointestinal Infectious Diseases.

Han Z, Min Y, Pang K, Wu D Int J Mol Sci. 2023; 24(21).

PMID: 37958637 PMC: 10650060. DOI: 10.3390/ijms242115654.

References

Huang Y, Yu J, Kang W, Ma Z, Ye X, Tian S . Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(11):e0142080. PMC: 4640555. DOI: 10.1371/journal.pone.0142080. View

Graham D, Lee Y, Wu M . Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2013; 12(2):177-86.e3. PMC: 3830667. DOI: 10.1016/j.cgh.2013.05.028. View

Pan M, Wan C, Xie Q, Huang R, Tao X, Shah N . Changes in gastric microbiota induced by Helicobacter pylori infection and preventive effects of Lactobacillus plantarum ZDY 2013 against such infection. J Dairy Sci. 2015; 99(2):970-981. DOI: 10.3168/jds.2015-10510. View

Del Piano M, Pagliarulo M, Tari R, Carmagnola S, Balzarini M, Lorenzini P . Correlation between chronic treatment with proton pump inhibitors and bacterial overgrowth in the stomach: any possible beneficial role for selected lactobacilli?. J Clin Gastroenterol. 2014; 48 Suppl 1:S40-6. DOI: 10.1097/MCG.0000000000000256. View

Onrust L, Baeyen S, Haesebrouck F, Ducatelle R, Van Immerseel F . Effect of in feed administration of different butyrate formulations on Salmonella Enteritidis colonization and cecal microbiota in broilers. Vet Res. 2020; 51(1):56. PMC: 7168884. DOI: 10.1186/s13567-020-00780-2. View

Mehling H, Busjahn A . Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013; 5(8):3062-73. PMC: 3775242. DOI: 10.3390/nu5083062. View

Morio F, Jean-Pierre H, Dubreuil L, Jumas-Bilak E, Calvet L, Mercier G . Antimicrobial susceptibilities and clinical sources of Dialister species. Antimicrob Agents Chemother. 2007; 51(12):4498-501. PMC: 2167981. DOI: 10.1128/AAC.00538-07. View

Chen M, Su C, Yang J, Lu C, Hou Y, Wu J . Baicalin, Baicalein, and Lactobacillus Rhamnosus JB3 Alleviated Helicobacter pylori Infections in Vitro and in Vivo. J Food Sci. 2018; 83(12):3118-3125. DOI: 10.1111/1750-3841.14372. View

Francavilla R, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G . Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol. 2013; 48(5):407-13. DOI: 10.1097/MCG.0000000000000007. View

10.

Matsui H, Takahashi T, Overby A, Murayama S, Yoshida H, Yamamoto Y . Mouse Models for Assessing the Protective Efficacy of Lactobacillus gasseri SBT2055 against Helicobacter suis Infection Associated with the Development of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Helicobacter. 2015; 20(4):291-8. DOI: 10.1111/hel.12203. View

11.

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9. DOI: 10.1056/NEJMoa001999. View

12.

Tack J, Janssen P . Emerging drugs for functional dyspepsia. Expert Opin Emerg Drugs. 2011; 16(2):283-92. DOI: 10.1517/14728214.2011.558502. View

13.

Shen Y, Zou Y, Chen X, Li P, Rao Y, Yang X . Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori. J Control Release. 2020; 328:575-586. DOI: 10.1016/j.jconrel.2020.09.025. View

14.

Noh C, Kim B, Hong G, Cheong J, Lee K . Effects of the Administration of Probiotics on Fecal Microbiota Diversity and Composition in Healthy Individuals. J Neurogastroenterol Motil. 2018; 24(3):452-459. PMC: 6034673. DOI: 10.5056/jnm17140. View

15.

Brawner K, Kumar R, Serrano C, Ptacek T, Lefkowitz E, Morrow C . Helicobacter pylori infection is associated with an altered gastric microbiota in children. Mucosal Immunol. 2017; 10(5):1169-1177. PMC: 5526746. DOI: 10.1038/mi.2016.131. View

16.

Yang C, Liang L, Lv P, Liu L, Wang S, Wang Z . Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial. Helicobacter. 2021; 26(6):e12856. DOI: 10.1111/hel.12856. View

17.

Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V . Are probiotics useful for therapy of Helicobacter pylori diseases?. Comp Immunol Microbiol Infect Dis. 2019; 64:99-108. DOI: 10.1016/j.cimid.2019.02.010. View

18.

Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H . Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002; 32(2):105-10. DOI: 10.1111/j.1574-695X.2002.tb00541.x. View

19.

Mao B, Gu J, Li D, Cui S, Zhao J, Zhang H . Effects of Different Doses of Fructooligosaccharides (FOS) on the Composition of Mice Fecal Microbiota, Especially the Bifidobacterium Composition. Nutrients. 2018; 10(8). PMC: 6115998. DOI: 10.3390/nu10081105. View

20.

Wroblewski L, Peek Jr R, Wilson K . Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010; 23(4):713-39. PMC: 2952980. DOI: 10.1128/CMR.00011-10. View